益肾通癃胶囊治疗前列腺增生症（肾虚血瘀型）疗效观察
发布时间：2019-05-13 07:40
【摘要】：随着国民经济的不断发展,我国正逐步进入老龄化社会,而作为老年男性的常见病——良性前列腺增生症(benign prostatic hyperplasia BPH)是老年男性的一种常见疾病及多发疾病,给老年男性患者的生活质量带来严重影响。尽管医药发展迅速,但其治疗方法与治疗效果仍不尽人意。中医药对该病的治疗不仅思路更宽广,且强调个体差异,辩证论治,相比西医在临床上有更明显优势。我的导师陈其华教授,从事中医男科学多年,经过反复临床实践与探索,总结出治疗良性前列腺增生症从肾论治,自拟“益肾通癃胶囊”治疗BPH。临床上获得良好效果,值得进一步推广与研究。目的:通过临床观察验证和探讨“益肾通癃胶囊”治疗前列腺增生症(肾虚血瘀型)的临床疗效及可能的作用机理;研究出一种有较好临床疗效的中成药;以期为当地中医药治疗BPH提供具有价值的方法和药物。方法:临床收集BPH患者84例,年龄50~70周岁,记录IPSS评分,中医证候评分,QOL评分,并B超检查其前列腺大小、残余尿量的测定,尿流率。1、对符合条件的病例按就诊的顺序排列,将患者分为三组,每组28例。2、实验组服用“益肾通癃胶囊”6粒/次,每日2次,连续8周;西药对照组服用“盐酸坦索罗辛”0.2mg,每日1次,连续8周;中成药对照组服用“癃闭舒胶囊”3粒/次,每日2次,连续8周。3、每个患者在观察治疗期间每2周复诊一次,疗程结束后一周内复诊调查患者:尿流率,IPSS评分,QOL评分,中医证候评分,B超检测前列腺大小及残余尿量,并记录所得数据。4、统计学处理:应用SPSS19.0软件使用t检验,秩和检验等,比较三组治疗效果,进行疗效评定和结果分析。结果:实验组治疗有效率为89.28%,西药对照组85.71%,中成药对照组75%,三组有效率比较,实验组与西药对照组差异无统计学意义(P0.05),实验组与中成药对照组比较差异有统计学意义(P0.05)。结论:通过相关指标观察,实验组有效率明显高于中成药对照组;且实验组在减轻患者的IPSS评分、中医证候评分,QOL评分等方面均优于西药对照组和中成药对照组,且有一定缩小前列腺体积作用。说明益肾通癃胶囊治疗良性前列腺增生症有较好疗效。
[Abstract]:With the continuous development of national economy, China is gradually entering an aging society. As a common disease of elderly men, benign prostatic hyperplasia (benign prostatic hyperplasia BPH) is a common disease and multiple diseases of elderly men. It has a serious impact on the quality of life of elderly male patients. Despite the rapid development of medicine, its treatment methods and therapeutic effects are still not satisfactory. Traditional Chinese medicine not only has a broader train of thought, but also emphasizes individual differences and dialectical treatment, which has more obvious advantages than western medicine in clinical practice. My mentor Professor Chen Qihua, engaged in male science of traditional Chinese medicine for many years, after repeated clinical practice and exploration, summed up the treatment of benign prostatic hyperplasia from the kidney, self-made "Yishen Tonglong capsule" for the treatment of BPH. Good clinical results are obtained, which is worthy of further promotion and research. Objective: to verify and explore the clinical efficacy and possible mechanism of "Yishen Tonglong capsule" in the treatment of benign prostatic hyperplasia (kidney deficiency and blood stasis type), and to study a kind of proprietary Chinese medicine with good clinical effect. In order to provide valuable methods and drugs for the treatment of BPH with local traditional Chinese medicine. Methods: 84 patients with BPH, aged 50 to 70 years old, were enrolled in this study. IPSS score, TCM syndrome score and QOL score were recorded. The prostate size, residual urine volume and urine flow rate were measured by B-ultrasound. According to the order of treatment, the patients were divided into three groups, 28 cases in each group. 2. The experimental group was treated with "Yishen Tonglong capsule" 6 tablets twice a day for 8 weeks. The western medicine control group was treated with "Tansoloxin Hydrochloride" 0.2 mg once a day for 8 weeks. The Chinese patent medicine control group was treated with "Longshuanshu capsule" 3 tablets twice a day for 8 weeks. 3. Each patient was revisited every 2 weeks during the observation and treatment period, and the patients were investigated within one week after the end of the course of treatment: urine flow rate, IPSS score, QOL score, TCM syndrome score, B-ultrasound measured prostate size and residual urine volume, and recorded the data. 4, statistical processing: using SPSS19.0 software to use t test, rank sum test, etc., to compare the therapeutic effects of the three groups. The curative effect was evaluated and the results were analyzed. Results: the effective rate was 89.28% in the experimental group, 85.71% in the western medicine control group and 75% in the Chinese patent medicine control group. There was no significant difference between the experimental group and the western medicine control group (P 0.05). There was significant difference between the experimental group and the control group (P 0.05). Conclusion: through the observation of related indexes, the effective rate of the experimental group is significantly higher than that of the traditional Chinese patent medicine control group. The experimental group was superior to the western medicine control group and the proprietary Chinese medicine control group in reducing the IPSS score, TCM syndrome score and QOL score of the patients, and had the effect of reducing the prostate volume to a certain extent. It shows that Yishentong long capsule has a good curative effect on benign prostatic hyperplasia.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R277.5
[Abstract]:With the continuous development of national economy, China is gradually entering an aging society. As a common disease of elderly men, benign prostatic hyperplasia (benign prostatic hyperplasia BPH) is a common disease and multiple diseases of elderly men. It has a serious impact on the quality of life of elderly male patients. Despite the rapid development of medicine, its treatment methods and therapeutic effects are still not satisfactory. Traditional Chinese medicine not only has a broader train of thought, but also emphasizes individual differences and dialectical treatment, which has more obvious advantages than western medicine in clinical practice. My mentor Professor Chen Qihua, engaged in male science of traditional Chinese medicine for many years, after repeated clinical practice and exploration, summed up the treatment of benign prostatic hyperplasia from the kidney, self-made "Yishen Tonglong capsule" for the treatment of BPH. Good clinical results are obtained, which is worthy of further promotion and research. Objective: to verify and explore the clinical efficacy and possible mechanism of "Yishen Tonglong capsule" in the treatment of benign prostatic hyperplasia (kidney deficiency and blood stasis type), and to study a kind of proprietary Chinese medicine with good clinical effect. In order to provide valuable methods and drugs for the treatment of BPH with local traditional Chinese medicine. Methods: 84 patients with BPH, aged 50 to 70 years old, were enrolled in this study. IPSS score, TCM syndrome score and QOL score were recorded. The prostate size, residual urine volume and urine flow rate were measured by B-ultrasound. According to the order of treatment, the patients were divided into three groups, 28 cases in each group. 2. The experimental group was treated with "Yishen Tonglong capsule" 6 tablets twice a day for 8 weeks. The western medicine control group was treated with "Tansoloxin Hydrochloride" 0.2 mg once a day for 8 weeks. The Chinese patent medicine control group was treated with "Longshuanshu capsule" 3 tablets twice a day for 8 weeks. 3. Each patient was revisited every 2 weeks during the observation and treatment period, and the patients were investigated within one week after the end of the course of treatment: urine flow rate, IPSS score, QOL score, TCM syndrome score, B-ultrasound measured prostate size and residual urine volume, and recorded the data. 4, statistical processing: using SPSS19.0 software to use t test, rank sum test, etc., to compare the therapeutic effects of the three groups. The curative effect was evaluated and the results were analyzed. Results: the effective rate was 89.28% in the experimental group, 85.71% in the western medicine control group and 75% in the Chinese patent medicine control group. There was no significant difference between the experimental group and the western medicine control group (P 0.05). There was significant difference between the experimental group and the control group (P 0.05). Conclusion: through the observation of related indexes, the effective rate of the experimental group is significantly higher than that of the traditional Chinese patent medicine control group. The experimental group was superior to the western medicine control group and the proprietary Chinese medicine control group in reducing the IPSS score, TCM syndrome score and QOL score of the patients, and had the effect of reducing the prostate volume to a certain extent. It shows that Yishentong long capsule has a good curative effect on benign prostatic hyperplasia.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R277.5
【参考文献】
相关期刊论文 前10条
1 陈其华;赵丹;王大进;易倩;欧阳政洁;;自拟方药益肾通癃胶囊治疗前列腺增生症疗效观察[J];中国性科学;2016年02期
2 程田坡;;联合应用TURP和TUVP治疗前列腺增生症132例疗效评价[J];中国医药指南;2013年36期
3 代睿欣;白遵光;胡萍;王昭辉;吕立国;朱首伦;潘俊;陈志强;;滋肾通关片治疗良性前列腺增生症的临床研究[J];中华中医药学刊;2013年07期
4 宋春生;赵家有;;通络法治疗前列腺疾病体会[J];中医杂志;2013年12期
5 徐波;董春来;魏永进;;前列安合剂治疗良性前列腺增生症64例临床研究[J];中国当代医药;2011年36期
6 刘丹荣;尤志s，
本文编号：2475710
本文链接：https://www.wllwen.com/zhongyixuelunwen/2475710.html
